RT @DrChoueiri: JUST IN: @FDA approves peri-operative PD-L1 inhibitor Durvalumab + EV in cis-ineligible/refusing Muscle-Invasive Bladder Caโฆ
Bicky Thapa retweeted
Clonal evolution. Wheler was here too but she left before the photo. Proud of these mentees and wonderful opportunity to see them at TargetCancer Foundation meeting for rare cancers. ๐งจ๐ฆ๐ฆ๐ฏ๐ก๐
Bicky Thapa retweeted
โญ๏ธ๐จNivolumab/Ipilimumab and Pembrolizumab for All Cancers: Australia's Landmark Tumor-Agnostic Immunotherapy Reimbursement | Journal of Clinical Oncology @JCO_ASCO @ASCO @Dr_R_Kurzrock @OncoAlert ascopubs.org/doi/10.1200/JCOโฆ
Bicky Thapa retweeted
Proud to see @NazliDizman @DanaFarber on the main stage at @SWOG in our GU planning session. Grateful to @PBarataMD @caseccc (PI of S2419, BIOFRONT) & @BraunMDPhD @YaleCancer (GU translational lead) for getting her involved in analyzing biomarker results in the 1st P3 study evaluating microbiome modulation to improve IO-outcomes!
Bicky Thapa retweeted
Such an honor to co-chair the WIN symposium with Wafik El Deiry
Bringing the Global Precision Oncology Community Together at WIN Symposium 2026 - Vivek Subbiah, MD
@VivekSubbiah @weldeiry @Dr_R_Kurzrock
oncodaily.com/voices/vivek-sโฆ
Bicky Thapa retweeted
Living the WIN conference. Molecular Tumor Boards everywhere. Who knew that when we coined the term and concept in 2014, it would take off Iike wild fire!!
๐ค Made with AI
Bicky Thapa retweeted
Congratulations to my good friend and colleague Mary-Ellen Taplin on the well deserved @PCFnews Women in Science Lifetime Achievement Award !
Thank you @PCF_Science for this important recognition!
@DanaFarber_GU @DanaFarber @DanaFarberNews @harvardmed
Bicky Thapa retweeted
๐จโญ๏ธWhat an energizing LIVE molecular tumor board at the WIN Symposium , Providence, RI @WIN_Consortium
worldโclass precision oncology faculty tackling real & challenging cases in real time @Dr_R_Kurzrock @weldeiry @bickythapa02 @SewantiLimaye
โญ๏ธImagine if every patient everywhere had access to this level of expert discussion & insight @OncoAlert @oncodaily
Bicky Thapa retweeted
The FDA voted in favor of the Galleri blood test for multicancer detection. @DanaFarber's @DrChoueiri tells @GoHealio this is an important milestone, but more long-term data are needed.
Read more: bit.ly/4xPVaZh
Bicky Thapa retweeted
JUST IN: @FDA approves the combo of Lenvatinib+HIF2 inhibitor Belzutifan in advanced clear cell renal cell carcinoma following PD1/L1 inhibitor. Results based on Litespark-011 trial led by @motzermd @DrDanielHeng @SchmidigerManu1
@ASCO @myESMO @AACR @kidneycan @DanaFarber_GU @OncoAlert
Bicky Thapa retweeted
Dr @RashadNawfal is an outstanding prospect for internal medicine residency. He is a superb physician and under his belt he has multi-year laboratory experience in liquid biopsies and epigenomics from my lab and the Freedman lab @DanaFarber @DanaFarber_GU
Hello #MedTwitter #MedX!
Iโm Rashad Nawfal, an #IMG from @LebaneseUni and a postdoctoral research fellow at @DanaFarber @harvardmed studying novel liquid biopsy tools for cancer epigenomics.
Excited to apply to #InternalMedicine for #Match2027!
AAMC ID: 15006561
#InsideTheMatch
Bicky Thapa retweeted
Iโm excited to join fellow experts and Shirley @leung at @BostonGlobe Mediaโs Future of Medicine Summit to discuss how cancer vaccines are rewriting the rules of treatment โ exploring how personalized mRNA vaccines are moving from moonshot ideas to real clinical trials with real patients and real benefits!
Join us on September 15 for a day of thought-provoking conversations about whatโs next in healthcare. Learn more and register at Globe.com/futureofmedicine. #FutureofMed2026
@DanaFarber @DanaFarber_GU @DanaFarberNews @OnlyInBOS @ScienceinBoston @harvardmed @TheVinodLab #MichelleBrown
Bicky Thapa retweeted
So thrilled to have you @neerajaiims with us at @DanaFarber! We are incredibly fortunate to welcome not only an outstanding prostate cancer oncologist, but also a terrific colleague and leader. Excited to see all that you will bring to our team and to the @Harvard Cancer Consortium #ProstateCancer Program.
Welcome to @CityOfBoston and to the family!
@DanaFarber_GU @harvardmed @DanaFarberNews @df_hcc
Thrilled to have joined @DanaFarber and to be working with an inspiring leader in oncology, @DrChoueiri. Delighted to serve as a faculty medical oncologist and Co-Director of the @Harvard Cancer Consortium #ProstateCancer Program. Excited for this new chapter!
Bicky Thapa retweeted
Very excited to welcome four outstanding new faculty to the Lank Center for Genitourinary Oncology @DanaFarber
1) Dr. Nazli Dizman @NazliDizman
2) Dr. Brian Russell @brian_russell39
3) Dr. Hamid Emamekhoo @HamidEmamekhoo
4) Pr. Neeraj Agarwal @neerajaiims
They bring complementary expertise spanning clinical investigation, microbiome science, informatics, quality improvement, education, and GU oncology.
Hamid and Neeraj will also take on important broader institutional leadership roles @DanaFarber and @Harvard Cancer Consortium @df_hcc
We are fortunate to have themโand the @DanaFarber_GU and our patients are in very good hands.
Welcome to @CityOfBoston and @DanaFarber!
Bicky Thapa retweeted
The 5-year follow-up from KY-564 now published in @Annals_Oncology --the first ever adjuvant trial in Kidney cancer continues to show a survival benefit now with OS at 5+years and in key subgroups!
annalsofoncology.org/articleโฆ
@HaasNaomi @tompowles1 @OncoAlert @OncBrothers @DanaFarber_GU @DanaFarber @harvardmed @AUC3_Official
Bicky Thapa retweeted
Have you ever wondered what takes place in a TCF-001 TRACK Virtual #MolecularTumorBoard meeting?
Watch to learn how biomarker testing and multi-disciplinary expertise come together to uncover treatment options for difficult-to-treat #RareCancers
targetcancer.short.gy/RCTT-2โฆ
Bicky Thapa retweeted
๐ฅ๐ฒ๐ด๐ถ๐๐๐ฒ๐ฟ ๐ฎ๐ป๐ฑ ๐๐๐ฏ๐บ๐ถ๐: bit.ly/WINSympo2026website
Program spotlight: ๐ช๐๐ก ๐๐ป๐๐ฒ๐ฟ๐ป๐ฎ๐๐ถ๐ผ๐ป๐ฎ๐น ๐ ๐ผ๐น๐ฒ๐ฐ๐๐น๐ฎ๐ฟ ๐ง๐๐บ๐ผ๐ฟ ๐๐ผ๐ฎ๐ฟ๐ฑ
At ๐ช๐๐ก ๐ฆ๐๐บ๐ฝ๐ผ๐๐ถ๐๐บ ๐ฎ๐ฌ๐ฎ๐ฒ, the WIN International Molecular Tumor Board will bring together multidisciplinary international experts for live case discussions from ๐ช๐๐ก ๐๐ผ๐ป๐๐ผ๐ฟ๐๐ถ๐๐บ institutions, with audience participation encouraged.
The tumor board will be chaired by ๐๐ฟ. ๐ฅ๐ฎ๐๐ฒ๐น๐น๐ฒ ๐๐๐ฟ๐๐ฟ๐ผ๐ฐ๐ธ, ๐ ๐, ๐๐๐๐ฃ, WIN Consortium, Chevilly-Larue, France, and Medical College of Wisconsin, Milwaukee, WI, USA.
Co-chairs include ๐๐ฟ. ๐ช๐ฎ๐ณ๐ถ๐ธ ๐๐น-๐๐ฒ๐ถ๐ฟ๐, ๐ ๐, ๐ฃ๐ต๐, ๐๐๐๐ฃ, WIN Consortium, Chevilly-Larue, France, and Brown University Health, Providence, RI, USA; and ๐๐ฟ. ๐ฆ๐ฒ๐๐ฎ๐ป๐๐ถ ๐. ๐๐ถ๐บ๐ฎ๐๐ฒ, ๐ ๐๐๐ฆ, ๐ ๐, ๐ ๐ฆ, WIN Consortium, Chevilly-Larue, France, and Sir H.N. Reliance Foundation Hospital and Research Centre, Mumbai, India.
Panelists include ๐๐ฟ. ๐๐ถ๐๐๐ฒ๐ฝ๐ฝ๐ฒ ๐๐๐ฟ๐ถ๐ด๐น๐ถ๐ฎ๐ป๐ผ, ๐ ๐, ๐ฃ๐ต๐; ๐๐ฟ. ๐ฉ๐ถ๐๐ฒ๐ธ ๐ฆ๐๐ฏ๐ฏ๐ถ๐ฎ๐ต, ๐ ๐; ๐๐ฟ. ๐๐ถ๐๐ฒ๐น๐น๐ฒ ๐. ๐ฆ๐ฎ๐๐น๐ป๐ถ๐ฒ๐ฟ ๐ฆ๐ต๐ผ๐น๐น๐ฒ๐ฟ, ๐ ๐; ๐ฎ๐ป๐ฑ ๐๐ฟ. ๐๐ถ๐ฐ๐ธ๐ ๐ง๐ต๐ฎ๐ฝ๐ฎ, ๐ ๐, ๐ ๐ฆ, ๐๐๐๐ฃ.
๐ฃ๐ผ๐๐๐ฒ๐ฟ ๐ฎ๐ฏ๐๐๐ฟ๐ฎ๐ฐ๐ ๐๐๐ฏ๐บ๐ถ๐๐๐ถ๐ผ๐ป ๐ฐ๐น๐ผ๐๐ฒ๐ ๐๐๐ด๐๐๐ ๐ฎ๐ญ, ๐ฎ๐ฌ๐ฎ๐ฒ. Register now and submit your abstract by the deadline.
WIN Symposium 2026, ๐ฒ๐ป๐ฑ๐ผ๐ฟ๐๐ฒ๐ฑ ๐ฏ๐ ๐๐ฆ๐๐ขยฎ, will take place ๐ข๐ฐ๐๐ผ๐ฏ๐ฒ๐ฟ ๐ฎ-๐ฏ, ๐ฎ๐ฌ๐ฎ๐ฒ ๐ถ๐ป ๐ฃ๐ฟ๐ผ๐๐ถ๐ฑ๐ฒ๐ป๐ฐ๐ฒ, ๐ฅ๐ต๐ผ๐ฑ๐ฒ ๐๐๐น๐ฎ๐ป๐ฑ, ๐จ๐ฆ๐.
#WINSympo2026 #PrecisionOncology #CancerResearch #Oncology #MolecularTumorBoard
ASCOยฎ and American Society of Clinical Oncologyยฎ are registered trademarks of the American Society of Clinical Oncology, Inc. Used with permission. This is not an ASCO sponsored event.
Bicky Thapa retweeted
๐ฅ๐ฒ๐ด๐ถ๐๐๐ฒ๐ฟ ๐ฎ๐ป๐ฑ ๐๐๐ฏ๐บ๐ถ๐: bit.ly/WINSympo2026website
๐๐ฎ๐ฟ๐น๐ ๐๐ถ๐ฟ๐ฑ ๐ฟ๐ฒ๐ด๐ถ๐๐๐ฟ๐ฎ๐๐ถ๐ผ๐ป for ๐ช๐๐ก ๐ฆ๐๐บ๐ฝ๐ผ๐๐ถ๐๐บ ๐ฎ๐ฌ๐ฎ๐ฒ closes on ๐๐๐ด๐๐๐ ๐ญ๐ฒ, ๐ฎ๐ฌ๐ฎ๐ฒ. ๐ฃ๐ผ๐๐๐ฒ๐ฟ ๐ฎ๐ฏ๐๐๐ฟ๐ฎ๐ฐ๐ ๐๐๐ฏ๐บ๐ถ๐๐๐ถ๐ผ๐ป has been extended to ๐๐๐ด๐๐๐ ๐ฎ๐ญ, ๐ฎ๐ฌ๐ฎ๐ฒ.
Explore ๐ง๐ฟ๐ฎ๐ป๐๐น๐ฎ๐๐ถ๐ผ๐ป๐ฎ๐น ๐ข๐ป๐ฐ๐ผ๐น๐ผ๐ด๐.
This session will highlight translational research, clinical trial design, novel therapies and the application of precision oncology across cancer types.
Session speakers include:
> ๐๐ฟ. ๐๐ถ๐๐๐ฒ๐ฝ๐ฝ๐ฒ ๐๐๐ฟ๐ถ๐ด๐น๐ถ๐ฎ๐ป๐ผ, ๐ ๐, ๐ฃ๐ต๐
University of Milano / European Institute of Oncology, Milan, Italy | President-Elect, ESMO 2027-2028
> ๐๐ฟ. ๐๐ฒ๐ป๐ฒ๐ฑ๐ถ๐๐ผ ๐. ๐๐ฎ๐ฟ๐ป๐ฒ๐ถ๐ฟ๐ผ, ๐ ๐, ๐ ๐ฆ
Legorreta Cancer Center, Brown University, Providence, RI, USA
> ๐๐ฟ. ๐๐ฒ๐ป๐ป๐ถ๐ณ๐ฒ๐ฟ ๐๐ฟ๐ฎ๐ป๐ฑ๐ถ๐, ๐ ๐
University of California San Francisco, San Francisco, CA, USA
> ๐๐ฟ. ๐๐ผ๐ฟ๐ป๐ฒ๐น๐ถ๐ฎ ๐ฃ๐ผ๐น๐๐ฎ๐ธ, ๐ ๐, ๐ฃ๐ต๐
Harvard Medical School / Dana-Farber Cancer Institute, Boston, MA, USA
๐ช๐๐ก ๐ฆ๐๐บ๐ฝ๐ผ๐๐ถ๐๐บ ๐ฎ๐ฌ๐ฎ๐ฒ is endorsed by ASCOยฎ*, supporting the scientific positioning of this yearโs program.
๐ฅ๐ฒ๐ด๐ถ๐๐๐ฒ๐ฟ ๐ฏ๐ ๐๐๐ด๐๐๐ ๐ญ๐ฒ ๐๐ผ ๐๐ฒ๐ฐ๐๐ฟ๐ฒ ๐๐ต๐ฒ ๐๐ฎ๐ฟ๐น๐ ๐๐ถ๐ฟ๐ฑ ๐ฟ๐ฎ๐๐ฒ.
๐ฆ๐๐ฏ๐บ๐ถ๐ ๐๐ผ๐๐ฟ ๐ฝ๐ผ๐๐๐ฒ๐ฟ ๐ฎ๐ฏ๐๐๐ฟ๐ฎ๐ฐ๐ ๐ฏ๐ ๐๐๐ด๐๐๐ ๐ฎ๐ญ.
#WINSympo2026 #PrecisionOncology #CancerResearch #Oncology #ClinicalResearch
*ASCOยฎ and American Society of Clinical Oncologyยฎ are registered trademarks of the American Society of Clinical Oncology, Inc. Used with permission. This is not an ASCO sponsored event.
Bicky Thapa retweeted
Breathtaking line up including Nobel Laureate. And Rhode Island is stunning
๐ฅ๐ฒ๐ด๐ถ๐๐๐ฒ๐ฟ ๐ฎ๐ป๐ฑ ๐๐๐ฏ๐บ๐ถ๐: bit.ly/WINSympo2026website
๐๐ฎ๐ฟ๐น๐ ๐๐ถ๐ฟ๐ฑ ๐ฟ๐ฒ๐ด๐ถ๐๐๐ฟ๐ฎ๐๐ถ๐ผ๐ป for ๐ช๐๐ก ๐ฆ๐๐บ๐ฝ๐ผ๐๐ถ๐๐บ ๐ฎ๐ฌ๐ฎ๐ฒ closes on ๐๐๐ด๐๐๐ ๐ญ๐ฒ, ๐ฎ๐ฌ๐ฎ๐ฒ. ๐ฃ๐ผ๐๐๐ฒ๐ฟ ๐ฎ๐ฏ๐๐๐ฟ๐ฎ๐ฐ๐ ๐๐๐ฏ๐บ๐ถ๐๐๐ถ๐ผ๐ป has been extended to ๐๐๐ด๐๐๐ ๐ฎ๐ญ, ๐ฎ๐ฌ๐ฎ๐ฒ.
Explore ๐๐ฟ๐ผ๐บ ๐๐ถ๐๐ฐ๐ผ๐๐ฒ๐ฟ๐ ๐๐ผ ๐๐ฒ๐น๐ถ๐๐ฒ๐ฟ๐ - ๐๐ฑ๐๐ฎ๐ป๐ฐ๐ถ๐ป๐ด ๐ฃ๐ฟ๐ฒ๐ฐ๐ถ๐๐ถ๐ผ๐ป ๐ข๐ป๐ฐ๐ผ๐น๐ผ๐ด๐ ๐ง๐ต๐ฟ๐ผ๐๐ด๐ต ๐ง๐ฟ๐ฎ๐ป๐๐น๐ฎ๐๐ถ๐ผ๐ป๐ฎ๐น ๐ฎ๐ป๐ฑ ๐ฅ๐ฒ๐ด๐๐น๐ฎ๐๐ผ๐ฟ๐ ๐๐ป๐ป๐ผ๐๐ฎ๐๐ถ๐ผ๐ป.
This session will examine how precision oncology is moving from molecular insight to clinical delivery, with discussion spanning molecular profiling, N-of-1 oncology, bedside-to-bench translational research, rational combination therapies and regulatory innovation.
Session speakers include:
> ๐๐ฟ. ๐ฅ๐ฎ๐๐ฒ๐น๐น๐ฒ ๐๐๐ฟ๐๐ฟ๐ผ๐ฐ๐ธ, ๐ ๐, ๐๐๐๐ฃ
WIN Consortium, Chevilly-Larue, France & Medical College of Wisconsin, Milwaukee, WI, USA
> ๐๐ฟ. ๐๐ฒ๐ถ๐๐ต ๐ง. ๐๐น๐ฎ๐ต๐ฒ๐ฟ๐๐, ๐ ๐, ๐๐๐๐๐ฅ
Massachusetts General Hospital / Harvard Medical School, USA | AACR President, Boston, MA, USA
> ๐๐ฟ. ๐ฅ๐ถ๐ฐ๐ต๐ฎ๐ฟ๐ฑ ๐ฃ๐ฎ๐๐ฑ๐๐ฟ, ๐ ๐
Former Director, FDA Oncology Center of Excellence, Washington, USA
Chaired by ๐๐ฟ. ๐ฅ๐ฎ๐๐ฒ๐น๐น๐ฒ ๐๐๐ฟ๐๐ฟ๐ผ๐ฐ๐ธ, ๐ ๐, ๐๐๐๐ฃ and ๐๐ฟ. ๐ช๐ฎ๐ณ๐ถ๐ธ ๐ฆ. ๐๐น-๐๐ฒ๐ถ๐ฟ๐, ๐ ๐, ๐ฃ๐ต๐, ๐๐๐๐ฃ.
WIN Symposium 2026 is endorsed by American Society Of Clinical Oncologyยฎ*, supporting the scientific positioning of this yearโs program.
๐ฅ๐ฒ๐ด๐ถ๐๐๐ฒ๐ฟ ๐ฏ๐ ๐๐๐ด๐๐๐ ๐ญ๐ฒ ๐๐ผ ๐๐ฒ๐ฐ๐๐ฟ๐ฒ ๐๐ต๐ฒ ๐๐ฎ๐ฟ๐น๐ ๐๐ถ๐ฟ๐ฑ ๐ฟ๐ฎ๐๐ฒ.
๐ฆ๐๐ฏ๐บ๐ถ๐ ๐๐ผ๐๐ฟ ๐ฝ๐ผ๐๐๐ฒ๐ฟ ๐ฎ๐ฏ๐๐๐ฟ๐ฎ๐ฐ๐ ๐ฏ๐ ๐๐๐ด๐๐๐ ๐ฎ๐ญ.
#WINSympo2026 #PrecisionOncology #CancerResearch #Oncology #TranslationalResearch
*ASCOยฎ and American Society of Clinical Oncologyยฎ are registered trademarks of the American Society of Clinical Oncology, Inc. Used with permission. This is not an ASCO sponsored event.
Bicky Thapa retweeted
๐ฅ๐ฒ๐ด๐ถ๐๐๐ฒ๐ฟ ๐ฎ๐ป๐ฑ ๐๐๐ฏ๐บ๐ถ๐: bit.ly/WINSympo2026website
๐๐ฎ๐ฟ๐น๐ ๐๐ถ๐ฟ๐ฑ ๐ฟ๐ฒ๐ด๐ถ๐๐๐ฟ๐ฎ๐๐ถ๐ผ๐ป for ๐ช๐๐ก ๐ฆ๐๐บ๐ฝ๐ผ๐๐ถ๐๐บ ๐ฎ๐ฌ๐ฎ๐ฒ closes on ๐๐๐ด๐๐๐ ๐ญ๐ฒ, ๐ฎ๐ฌ๐ฎ๐ฒ. ๐ฃ๐ผ๐๐๐ฒ๐ฟ ๐ฎ๐ฏ๐๐๐ฟ๐ฎ๐ฐ๐ ๐๐๐ฏ๐บ๐ถ๐๐๐ถ๐ผ๐ป has been extended to ๐๐๐ด๐๐๐ ๐ฎ๐ญ, ๐ฎ๐ฌ๐ฎ๐ฒ.
Explore ๐๐ฟ๐ผ๐บ ๐๐ถ๐๐ฐ๐ผ๐๐ฒ๐ฟ๐ ๐๐ผ ๐๐ฒ๐น๐ถ๐๐ฒ๐ฟ๐ - ๐๐ฑ๐๐ฎ๐ป๐ฐ๐ถ๐ป๐ด ๐ฃ๐ฟ๐ฒ๐ฐ๐ถ๐๐ถ๐ผ๐ป ๐ข๐ป๐ฐ๐ผ๐น๐ผ๐ด๐ ๐ง๐ต๐ฟ๐ผ๐๐ด๐ต ๐ง๐ฟ๐ฎ๐ป๐๐น๐ฎ๐๐ถ๐ผ๐ป๐ฎ๐น ๐ฎ๐ป๐ฑ ๐ฅ๐ฒ๐ด๐๐น๐ฎ๐๐ผ๐ฟ๐ ๐๐ป๐ป๐ผ๐๐ฎ๐๐ถ๐ผ๐ป.
This session will examine how precision oncology is moving from molecular insight to clinical delivery, with discussion spanning molecular profiling, N-of-1 oncology, bedside-to-bench translational research, rational combination therapies and regulatory innovation.
Session speakers include:
> ๐๐ฟ. ๐ฅ๐ฎ๐๐ฒ๐น๐น๐ฒ ๐๐๐ฟ๐๐ฟ๐ผ๐ฐ๐ธ, ๐ ๐, ๐๐๐๐ฃ
WIN Consortium, Chevilly-Larue, France & Medical College of Wisconsin, Milwaukee, WI, USA
> ๐๐ฟ. ๐๐ฒ๐ถ๐๐ต ๐ง. ๐๐น๐ฎ๐ต๐ฒ๐ฟ๐๐, ๐ ๐, ๐๐๐๐๐ฅ
Massachusetts General Hospital / Harvard Medical School, USA | AACR President, Boston, MA, USA
> ๐๐ฟ. ๐ฅ๐ถ๐ฐ๐ต๐ฎ๐ฟ๐ฑ ๐ฃ๐ฎ๐๐ฑ๐๐ฟ, ๐ ๐
Former Director, FDA Oncology Center of Excellence, Washington, USA
Chaired by ๐๐ฟ. ๐ฅ๐ฎ๐๐ฒ๐น๐น๐ฒ ๐๐๐ฟ๐๐ฟ๐ผ๐ฐ๐ธ, ๐ ๐, ๐๐๐๐ฃ and ๐๐ฟ. ๐ช๐ฎ๐ณ๐ถ๐ธ ๐ฆ. ๐๐น-๐๐ฒ๐ถ๐ฟ๐, ๐ ๐, ๐ฃ๐ต๐, ๐๐๐๐ฃ.
WIN Symposium 2026 is endorsed by American Society Of Clinical Oncologyยฎ*, supporting the scientific positioning of this yearโs program.
๐ฅ๐ฒ๐ด๐ถ๐๐๐ฒ๐ฟ ๐ฏ๐ ๐๐๐ด๐๐๐ ๐ญ๐ฒ ๐๐ผ ๐๐ฒ๐ฐ๐๐ฟ๐ฒ ๐๐ต๐ฒ ๐๐ฎ๐ฟ๐น๐ ๐๐ถ๐ฟ๐ฑ ๐ฟ๐ฎ๐๐ฒ.
๐ฆ๐๐ฏ๐บ๐ถ๐ ๐๐ผ๐๐ฟ ๐ฝ๐ผ๐๐๐ฒ๐ฟ ๐ฎ๐ฏ๐๐๐ฟ๐ฎ๐ฐ๐ ๐ฏ๐ ๐๐๐ด๐๐๐ ๐ฎ๐ญ.
#WINSympo2026 #PrecisionOncology #CancerResearch #Oncology #TranslationalResearch
*ASCOยฎ and American Society of Clinical Oncologyยฎ are registered trademarks of the American Society of Clinical Oncology, Inc. Used with permission. This is not an ASCO sponsored event.

































